Search Within

Maurie Markman

Formats
  1. Journal Article (88)
  2. Meeting Abstract (29)
  3. Conference Paper (6)
  4. Review (1)
Groups
  1. Surgery (69)
  2. Nursing (42)
  3. Department of Medicine (12)
  4. Solid Tumor Oncology Division (11)
  5. Center for Pancreatic Cancer Research (6)
  6. Gastrointestinal Oncology Service (5)

More Groups

People
  1. William Hoskins (66)
  2. Thomas Hakes (64)
  3. Stephen Rubin (60)
  4. John Lewis (59)
  5. Bonnie Reichman (55)
  6. Walter Jones (43)

More People

Years
  1. 1997 (1)
  2. 1996 (1)
  3. 1995 (1)
  4. 1994 (4)
  5. 1993 (10)
  6. 1992 (21)

More Years

Publications
  1. Clinical Research (26)
  2. Gynecologic Oncology (21)
  3. Journal of Clinical Oncology (18)
  4. Journal of Cancer Research and Clinical Oncology (9)
  5. Seminars in Oncology (6)
  6. American Journal of Obstetrics and Gynecology (3)

More Publications

Publishers
  1. SLACK, Inc. (26)
  2. Elsevier B.V. (21)
  3. American Society of Clinical Oncology (18)
  4. Elsevier Inc. (15)
  5. Springer (15)
  6. Lippincott Williams & Wilkins (7)

More Publishers

Results (124)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Intraperitoneal chemotherapy as treatment for diseases principally confined to the peritoneal cavity
    Meeting Abstract

    Markman, M.
    Investigational New Drugs (1987)

    Fulltext@MSK | Save
  • Lack of efficacy of recombinant gamma-interferon (rGI) administered by the intraperitoneal (IP) route as therapy of refractory ovarian carcinoma (ROC)
    Meeting Abstract

    Markman, M.; D'Acquisto, R.; Hakes, T.; Rubin, S.; Hoskins, W.; Lewis, J. L. Jr
    Clinical Research (1987)

    Fulltext@MSK | Save
  • High dose intravenous cisplatin (DDP) with simultaneous intravenous sodium thiosulfate: A preliminary report
    Meeting Abstract

    Markman, M.; D'Acquisto, R.; Hakes, T.; Bajorin, D.; Kris, M.; Magill, G.; Bosl, G.
    Clinical Research (1987)

    Fulltext@MSK | Save
  • Recombinant gamma-interferon (rGI) administered by the intraperitoneal (IP) route as treatment of refractory ovarian carcinoma (ROC)
    Meeting Abstract

    D'Acquisto, R.; Markman, M.; Hakes, T.; Rubin, S.; Hoskins, W.; Lewis, J. L. Jr
    Clinical Research (1987)

    Fulltext@MSK | Save
  • Combination intravenous (IV) and intraperitoneal (IP) 5-fluorouracil (5-FU) therapy of malignant disease principally confined to the peritoneal cavity (PC)
    Meeting Abstract

    Reichman, B.; Markman, M.; Hakes, T.; Rubin, S.; Hoskins, W.; Lewis, J. L. Jr
    Clinical Research (1987)

    Fulltext@MSK | Save
  • Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
    Journal Article

    Howell, S. B.; Zimm, S.; Markman, M.; Abramson, I. S.; Cleary, S.; Lucas, W. E.; Weiss, R. J.
    Journal of Clinical Oncology (1987)

    Fulltext@MSK | Save
  • Intraperitoneal chemotherapy for malignant diseases of the gastrointestinal tract
    Journal Article

    Markman, M.
    Surgery, Gynecology and Obstetrics (1987)

    Fulltext@MSK | Save
  • The intracavitary administration of cytarabine to patients with nonhematopoietic malignancies: An update
    Journal Article

    Markman, M.; Howell, S. B.
    Seminars in Oncology (1987)

    Fulltext@MSK | Save
  • Current status of intracavitary chemotherapy
    Journal Article

    Markman, M.
    Oncology (Norwalk) (1987)

    Fulltext@MSK | Save
  • Intraperitoneal chemotherapy as treatment of ovarian carcinoma: Why, how, and when?
    Journal Article

    Markman, M.
    Obstetrical and Gynecological Survey (1987)

    Fulltext@MSK | Save